27.06.2024,
3819 Zeichen
Ramat Gan, Israel (OTS) - Medasense, a global leader in pain
monitoring solutions, is proud to announce a strategic partnership
with Nihon Kohden for the exclusive distribution of its revolutionary
pain monitoring device in Japan. This partnership is intended to
transform pain management practices across Japanese healthcare
facilities, offering a significant advancement in patient care.
Nihon Kohden, renowned for its history of excellence in providing
innovative high quality, reliable medical technology that improves
the way healthcare is practiced, is partnering with Medasense to
introduce its nociception monitor to the Japanese market. This
cutting-edge device, with its state-of-the-art AI powered NOL -
Nociception Level Index®, provides real-time, objective pain
monitoring, enabling the personalization and optimization of pain
treatment. It will be accessible to hospitals and clinics throughout
Japan through Nihon Kohden's extensive distribution channels pending
regulatory approval.
Medasense's CEO & Founder, Galit Zuckerman, expressed enthusiasm
about the collaboration: "We are honored to partner with Nihon
Kohden, a company with a long history of excellence, that shares our
vision of improving patient care through innovative solutions. Our
mission is to help all patients suffer less from pain and the adverse
effects of pain medication. Nihon Kohden's established clinical,
technological leadership and expertise in the Japanese market make
them the perfect partner to distribute our nociception monitor."
NOL monitoring provides an AI powered, clinically validated index
to objectively quantify the physiological response to pain
(nociception) supporting clinicians in delivering personalized
anesthesia tailored to patient requirements. With over 40 peer
reviewed publications, clinical studies have demonstrated that
NOL-guided analgesia resulted in intraoperative opioid sparing, and
improved post operative pain scores and patient recovery.1,2
About Medasense and NOL – Nociception Level Index® Technology
[Watch Medasense's 1-minute video] (
https://youtu.be/-JQevE0Vgl4)
About Nihon Kohden
<a>rachel@medasense.com</a>
For more information:
For more information about Medasense and Nihon Kohden, please visit
www.medasense.com and www.nihonkohden.com/.
Medasense is transforming pain management with its breakthrough
technology that empowers clinicians to optimize and personalize pain
control, significantly reducing the risk of pain or of
overmedication. The company's flagship product, the PMD-200™,
equipped with the NOL-Nociception Level Index®, leverages advanced
artificial intelligence and a proprietary non-invasive sensor system.
This unique platform provides objective monitoring and quantification
of a patient's pain response, making it an essential tool in an
operating room and critical care unit settings where patients cannot
communicate their pain levels. The PMD-200 is the first and only
monitor to be authorized by the FDA for pain measurement for
anaesthesiology. It has been used in over 100,000 surgeries
worldwide, and is commercially available in the US, Europe, Canada,
Latin America and Israel.
Watch Medasense's 1-minute videoFounded in 1951, Nihon Kohden is a
global leader of medical solutions with the goal to improve
healthcare with advanced technology. For more than 70 years, Nihon
Kohden has continued to provide a wide range of medical electronic
equipment including EEG, EMG/EP measuring systems,
electrocardiographs, bedside monitors, defibrillators, AEDs,
ventilators, and hematology instruments.
Nihon Kohden utilizes cutting-edge technology to support medical
treatment in all clinical areas, integrating medical devices into the
IT network to meet customers' requirements and offers a wide,
comprehensive solution.
Digital press kit:
http://www.ots.at/pressemappe/PR175502/aom
BSN Podcasts
Christian Drastil: Wiener Börse Plausch
Wiener Börse Party #692: Gottfried Neumeister Kurstrigger für Pierer Mobility Aktie, Erinnerung an Mariella Schurz, 5 Jahre Addiko
Aktien auf dem Radar:Amag, Agrana, RHI Magnesita, Austriacard Holdings AG, Flughafen Wien, Addiko Bank, Rosgix, ATX, ATX Prime, ATX TR, Wienerberger, Bawag, AT&S, Österreichische Post, Palfinger, Semperit, Cleen Energy, Pierer Mobility, UBM, Wiener Privatbank, Oberbank AG Stamm, CA Immo, Erste Group, EVN, Immofinanz, Telekom Austria, Uniqa, VIG.
Valneva
Valneva ist ein Impfstoffunternehmen, das sich auf die Entwicklung und Vermarktung von prophylaktischen Impfstoffen gegen Infektionskrankheiten mit hohem ungedeckten medizinischen Bedarf spezialisiert hat.
>> Besuchen Sie 68 weitere Partner auf boerse-social.com/partner
Mehr aktuelle OTS-Meldungen HIER